Trial reportAnnals of surgery2025
Reduction of Central Venous Pressure in Elective Robotic and Laparoscopic Liver Resection: The PRESSURE Trial-A Randomized Clinical Study.
Trial report in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Safety and outcomes of hemodilutional autologous transfusion in intermediate- to advanced-level liver resection: a prospective observational study.Surgery today · 2026Article
- Robotic versus laparoscopic anatomical hepatectomy: a post hoc analysis of the ROC'N'ROLL randomized controlled trial.Surgical endoscopy · 2026Article
- Balancing safety and outcomes in minimally invasive liver resection: insights from the PRESSURE trial.Hepatobiliary surgery and nutrition · 2026Article
- Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.Cancer biology & medicine · 2026Review
- Does complexity compromise outcomes in robotic hepatectomy?Surgical endoscopy · 2026Article
- Safety of robotic hepatic parenchymal transection using scissor hepatectomy and alternative techniques: a cohort study.Surgical endoscopy · 2026Article
- Robotic right living donor hepatectomy with intermittent inflow occlusion: true clinical benefit or just another chapter in the ischemic preconditioning story?Translational gastroenterology and hepatology · 2026Article
- Bilateral thoracic paravertebral block for robotic hepatectomy without hepatic portal occlusion for a cirrhosis patient: a case report.Frontiers in oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare perioperative outcomes in patients undergoing minimally invasive liver surgery (MILR) with or without central venous pressure (CVP) reduction (≤5 mm Hg).
backgroundReduction of CVP during parenchymal transection is widely accepted in open hepatectomy to reduce intraoperative blood loss, as a major predictor of postoperative outcomes. However, the effect of CVP reduction on blood loss in MILR remains unclear.
methodsThis study is a randomized controlled, double-blinded trial. Patients undergoing elective MILR between August 2020 and April 2023 were equally randomized to either no CVP reduction (No CVP reduction group) or CVP reduction by anesthesiological interventions (CVP reduction group). The remaining perioperative care was kept identical between groups. The primary endpoint was total intraoperative blood loss.
resultsIn total, 120 patients were randomized and 112 were analyzed. Baseline characteristics did not differ between groups. Total intraoperative blood loss in MILR was equivalent between groups [No CVP reduction: 280 mL (120-560) vs CVP reduction: 360 mL (150-640); P = 0.30], despite higher CVP values during resection in the No CVP reduction group (9.3 mm Hg ± 4.2 vs 3.2 mm Hg ± 2.2; P < 0.001). Similarly, there was no difference in blood loss during parenchymal transection between the No CVP reduction (220 mL; 80-400) and the CVP reduction group (240 mL; 110-560; P = 0.39). Postoperative 90-day mortality (No CVP reduction: n=3, 5% versus CVP reduction: n=2, 4%; P = 0.68) and total morbidity rates (No CVP reduction: n = 10, 18% vs CVP reduction: n = 11, 20%; P = 0.77) were comparable. Intraoperative hemodynamic instability was less frequent in the No CVP reduction group (n = 7, 12% vs CVP reduction group: n = 16, 30%; P = 0.03).
conclusionsMILR without CVP reduction during liver transection is safe and is not associated with increased intraoperative blood loss. Moreover, a no CVP reduction strategy might prevent potential adverse effects of fluid restriction in MILR, such as hemodynamic instability.
Indexed as
Identifiers
40197483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.